Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
60 Degrees PharmaceuticalsSXTP 44 Cash Ratio is 1.78 as of Mar. 2026, which is 78% above its 10-year median of 1.00. GuruFocus rates SXTP with a GF Score™ of 44/100 and a GF Value™ of $1.99 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,383 Biotechnology companies, 60 Degrees Pharmaceuticals ranks worse than 62.11% on this metric.
60 Degrees Pharmaceuticals has a Cash Ratio of 1.78. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for 60 Degrees Pharmaceuticals's Cash Ratio or its related term are showing as below:
SXTP'
s Cash Ratio Range Over the Past 10 Years
Min: 0.01 Med: 1 Max: 3.83
Current: 1.78
During the past 6 years, 60 Degrees Pharmaceuticals's highest Cash Ratio was 3.83. The lowest was 0.01. And the median was 1.00.
SXTP's Cash Ratio is ranked worse than 62.11% of 1383
companies
in the Biotechnology industry
Industry Median: 2.93
vs SXTP: 1.78
60 Degrees Pharmaceuticals (NAS:SXTP) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
60 Degrees Pharmaceuticals Cash Ratio Related Terms
60 Degrees Pharmaceuticals Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, 60 Degrees Pharmaceuticals's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
60 Degrees Pharmaceuticals Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 60 Degrees Pharmaceuticals's Cash Ratio distribution charts can be found below:
* The bar in red indicates where 60 Degrees Pharmaceuticals's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
60 Degrees Pharmaceuticals (SXTP) has a Cash Ratio of 1.78 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on 60 Degrees Pharmaceuticals and its competitors. This is 78% above median its historical median of 1.00. Over the past decade, 60 Degrees Pharmaceuticals' Cash Ratio has ranged from 0.01 to 3.83. According to the industry distribution chart, 60 Degrees Pharmaceuticals ranks #859 out of 1383 companies in the Biotechnology industry, placing it in the top 62.1%.
Is 60 Degrees Pharmaceuticals' Cash Ratio too high?
60 Degrees Pharmaceuticals' current Cash Ratio of 1.78 is 78% above median its 10-year median of 1.00. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 3.83. The Biotechnology industry median Cash Ratio is 2.93. 60 Degrees Pharmaceuticals' value of 1.78 is 39.2% below this industry median. Based on the distribution chart, 60 Degrees Pharmaceuticals ranks #859 out of 1383 companies in the Biotechnology industry, which is below the industry midpoint. Overall, 60 Degrees Pharmaceuticals has a GF Score™ of 44/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does 60 Degrees Pharmaceuticals' Cash Ratio compare to GLMD and FBLG?
According to the Biotechnology industry distribution chart, 60 Degrees Pharmaceuticals ranks #859 out of 1383 companies for Cash Ratio. This places 60 Degrees Pharmaceuticals in the lower half of its industry. The industry median Cash Ratio is 2.93. 60 Degrees Pharmaceuticals' value of 1.78 is 39.2% below this benchmark. Historically, 60 Degrees Pharmaceuticals' own Cash Ratio has ranged from 0.01 to 3.83 over the past decade. While the company's 10-year median is 1.00 vs. the industry median of 2.93, 60 Degrees Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,383 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 60 Degrees Pharmaceuticals's current Cash Ratio of 1.78 is 39.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on 60 Degrees Pharmaceuticals and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 60 Degrees Pharmaceuticals's current Cash Ratio is 1.78, which is 78% above median its own 10-year median of 1.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 60 Degrees Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, 60 Degrees Pharmaceuticals (SXTP) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.99, compared to a current price of $1.48 — trading 25.6% below its estimated fair value. The current Cash Ratio is 1.78, which is 78% above median its 10-year median of 1.00 and 39.2% below the Biotechnology industry median of 2.93. 60 Degrees Pharmaceuticals' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For 60 Degrees Pharmaceuticals (SXTP), the current Cash Ratio is 1.78 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 60 Degrees Pharmaceuticals (SXTP) Overvalued in 2026?
Based on GuruFocus' analysis, 60 Degrees Pharmaceuticals stock appears to be undervalued.
The current stock price of $1.48 is trading 25.6% below its estimated GF Value™ of $1.99.
GuruFocus considers 60 Degrees Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for SXTP:
Cash Ratio: 1.78 (78% above median its 10-year median of 1.00)
GF Value™: $1.99 vs. price of $1.48 (25.6% below fair value)
Industry Position: 39.2% below the Biotechnology median (#859 of 1383)
No single metric tells the full story. See the SXTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.
44GF Score
Get the complete analysis for SXTP
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SXTP has been successfully added to your 
